Publication of Circular and RTW Bio Prospectus
|
Arix Bioscience PLC (ARIX)
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL, OR THE SOLICITATION OF AN OFFER TO ACQUIRE, ANY SECURITIES IN FOR IMMEDIATE RELEASE
Legal Entity Identifier: 213800OVT3AHQCXNIX43
RECOMMENDED ALL-SHARE ACQUISITION OF THE ASSETS OF ARIX BIOSCIENCE PLC ("Arix") BY RTW BIOTECH OPPORTUNITIES LTD ("RTW Bio") Publication of Circular and RTW Bio Prospectus On Arix is pleased to announce that the circular in relation to the Scheme (the "Circular"), together with the associated Form of Proxy, is today being sent, or made available, to Shareholders and, for information only, to persons with information rights. The Circular contains, amongst other things, the full terms and conditions of the Scheme, a letter from the Chairman of Arix, an expected timetable of principal events, notice of the First General Meeting and details of the actions to be taken by Shareholders entitled to vote at the First General Meeting. The Circular will be made available on Arix's website at https://arixbioscience.com/investor-relations. Arix also notes that RTW Bio will, subject to FCA approval, today publish a prospectus relating to the new shares to be issued to eligible Shareholders by RTW Bio under the terms of the Scheme (the "RTW Bio Prospectus"). The RTW Bio Prospectus will be made available, free of charge, in electronic form on RTW Bio's website at https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/documents/ Copies of the RTW Bio Prospectus and Circular will be submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Capitalised terms used but not defined in this announcement have the meanings given to them in the Circular. All references in this announcement to times are to times in Irrevocable Undertakings Since publication of the Original Announcement, Arix has also received irrevocable undertakings from Arix directors Together with the irrevocable undertakings of Peregrine Moncreiffe, Notice of First General Meeting As further detailed in the Circular, to become effective, the Scheme will require, among other things, the approval of Shareholders at the General Meetings. The Scheme can only become effective if all Conditions to the Scheme, including Shareholder approval, have been satisfied (unless, where applicable, the relevant Condition is waived). Notice of the First General Meeting, which will be held at Clifford Chance LLP, Shareholders are requested to complete, sign and return the Form of Proxy (once received), or appoint a proxy through the CREST electronic proxy appointment service (as appropriate), for the First General Meeting (where entitled to do so), as soon as possible. Recommendation The Special Committee, which has been so advised by Jefferies, considers that the Scheme and the Resolutions to be proposed at the General Meetings are in the best interests of Shareholders as a whole. In providing its advice to the Special Committee, Jefferies has taken into account the commercial assessments of the Special Committee. Shareholders should read the Circular in its entirety, and are recommended to read the further information set out in the RTW Bio Prospectus before making a decision with respect to the Scheme. If you have any queries, please call the Registrars, Equiniti, Expected Timetable of Principal Events The Circular contains an expected timetable of principal events relating to the Scheme, which is also set out in the appendix to this announcement. Subject to obtaining the approval of Shareholders at the General Meetings, and the satisfaction or, where applicable, waiver of the other Conditions, the Scheme is expected to become effective in the first quarter of 2024. The dates given are indicative only and are based on Arix's current expectations and may be subject to change (including as a result of changes to the regulatory timetable and/or the process for implementation of the Scheme). If any of the times and/or dates set out in the appendix change, the revised times and/or dates will be notified by Arix to Shareholders through a Regulatory Information Service.
Enquiries:
Important information
Jefferies International Limited ("Jefferies"), which is authorised and regulated by the Financial Conduct Authority in the
Notice to US Shareholders in Arix This announcement is not for publication or distribution, directly or indirectly, in or into The Consideration Shares will be offered and sold for investment purposes only in RTW Bio is not registered, and does not intend to be subject to registration, as an investment company under the 1940 Act in reliance upon one or more exclusions or exemptions from registration thereunder. The Consideration Shares are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under the Securities Act, the 1940 Act and any applicable state and other securities laws, pursuant to registration or an exclusion or exemption therefrom. The transferability of the Consideration Shares will be further restricted by the terms of the AI/QP Investor Letter, and any re-offer or resale of any Consideration Shares in General If you are in any doubt about the contents of this announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor or independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are resident in the
APPENDIX Expected Timetable of Principal Events
The dates and times given in the table below in connection with the Scheme are indicative only and are based on the Company's current expectations and may be subject to change (including as a result of changes to the process for implementation of the Scheme). If any of the times and/or dates below change, the revised times and/or dates will be notified by the Company to Shareholders through a Regulatory Information Service.
(*) All references to "S+1" are to the day falling one Business Day after the actual date which is "S". All references to times are to times in Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
| ISIN: | GB00BD045071 |
| Category Code: | PDI |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 295601 |
| EQS News ID: | 1808727 |
| End of Announcement | EQS News Service |
|
|
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE